Influenza Articles
Results from a recent study suggest coupling HA molecules from various flu strains could make flu vaccines more effective.
A study led by researchers at Stanford Medicine has shown that variation in vaccine durability can, in part, be attributed to a type of blood cell called megakaryocytes, typically implicated in blood clotting.
According to a recent study published in JAMA Network Open, the estimated effectiveness of at least one dose of the influenza vaccine against emergency department visits or hospitalization was over 50 percent across disease severity levels among nearly 16,000 U.S. children during five respiratory illness seasons.
The U.S. Food and Drug Administration (FDA) has authorized the first over-the-counter combination COVID-19 and influenza test, the Healgen Rapid Check COVID-19/Flu A&B Antigen Test, outside of emergency use.
Scientists at Harvard Medical School have developed a simple nasal spray, made of harmless ingredients, that can protect people against flu, colds and COVID-19 with near-100 percent success, and it costs just $25.
The first influenza nasal spray vaccine that can be self-administered has been approved by the U.S. Food and Drug Administration (FDA).
A new vaccine may help speed up the process of making antibodies against SARS-CoV-2 by using preexisting immunity to a separate virus (the influenza virus).
A Phase I/II study evaluating the safety, tolerability and immunogenicity of Pfizer and BioNTech's mRNA-based combination vaccine candidates for influenza and COVID-19 among healthy adults 18 to 64 years of age show positive topline results.
A study by researchers at Georgia State University's Institute of Biomedical Sciences has found a new universal flu vaccine has been found to protect against influenza B viruses that offer broad defenses against different strains and improve immune protection.
Despite technical challenges, some companies are working on making a combination COVID and flu vaccine.
Researchers in a study funded by the National Institute of Allergy and Infectious Diseases and the National Institutes of Health have developed an influenza (flu) vaccine administered through the nose that has been constructed with nanoparticles and offers stronger protection.
Two studies show the influenza (flu) and pneumonia vaccines lessen the risk of developing Alzheimer’s disease (AD) in the future.
